

An Integrated Target-to-Lead Platform for Drug Discovery: We Validate Concepts, Identify New Chemical Matter, Build Value for Pharma/Biotech/VC

Christoph Sachse. NUVISAN ICB GmbH, Müllerstraße 178, 13353 Berlin, Germany

NUVISAN is a fully integrated "Science CRO" with ~1,000 staff and 5 sites in Germany and France. Our Berlin operations have been sold out of a major pharma R&D operation, and consequently, decades of successful expertise are now available for our pharma, biotech and VC clients. We offer all necessary functions covering lead discovery, computational & medicinal chemistry, *in vitro* & *in vivo* pharmacology, DMPK & toxicology. We have access to cutting-edge technologies including CRISPR and iPSC. We provide our work in fee-for-service and FTE capacity-based contracts.

Background




Track Record




From concept stage to the clinic, our drug discovery team in Berlin has successfully contributed to a wide range of pharma programs.

Compound Libraries



- Highest chemical diversity
- >90% unique and proprietary compounds
- In vitro and in vivo data from historical screens connected to guide hit selection
- Hit expansion into the full deck possible when screening any of the subsets.


* Library parts available for virtual screening approaches.




Chemical diversity comparison of our industry-leading 3 million molecules collection (Ultra HTS + Goldrand + NGLI, in blue) and NUVISAN Explorer lead-like library of 340 k (orange) based on the tSNE analysis of Murcko scaffolds. The Ultra HTS deck brings vast chemical diversity and high structural quality based on the long-lasting pharma heritage; the NUVISAN Explorer library maintains a significant chemical diversity despite its smaller size, ensuring lead-like chemical matter for a wide range of biological targets.

NUVISAN Explorer Library Ultra HTS Deck + Goldrand + NGLI



Hit Identification




HTS Capabilities




High-Content Screening




Hit-to-Lead, Lead Opt, Preclinical



Portfolio



PROTACS Platform



Learn More

NUVISAN ICB GmbH
Müllerstraße 178
13353 Berlin
Germany

www.nuvisan.com
hello@nuvisan.com



insights.nuvisan.com